Shots:The UK’s MHRA has approved Otulfi (SC & IV), biosimilar of J&J’s Stelara (ustekinumab), to treat mod. to sev. active Crohn's disease, ulcerative colitis, plaque psoriasis as well as active psoriatic arthritis & is set to enter UK market as per a confidential settlement b/w the companies and J&J. It is approved across the US,…
Shots: To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research Continuing the series for the disease of the month, PharmaShots presents a condensed report on Ulcerative Colitis, which causes inflammation and sores (ulcers) in the digestive…
In an interview with PharmaShots, Jan Wehkamp, M.D., Vice President, Gastroenterology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development shared his views on the data from 13 P-II & III studies of Stelara (ustekinumab) for the treatment of IBD and other approved indicationsShots:The company has reported the data from 13 P-II & III studies, including 6 studies…
In an interview with PharmaShots, Dr. Pierre Pellier, CEO of CTMA, share his views on CT-SCOUT that helps to boost patient recruitment in the clinical trials for IBDShots:CTMA developed the web mobile platform, CT-Scout to boost patient recruitment in the clinical trials by facilitating a quick and simple study detection for eligible patientsCT-Scout is currently available in…
